HEPATITIS C VIRUS TREATMENT STATUS AMONG PATIENTS IN METHADONE MAINTENANCE TREATMENT IN LONG BIEN DISTRICT MEDICAL CENTER, HANOI 2024

Le Thanh Ha1,, Do Manh Hung2, Bui Thi Phuong3
1 Long Bien District Medical Center, Ha Noi
2 Viet Nam National Children’s Hospital
3 Hanoi University of Public Health

Nội dung chính của bài viết

Tóm tắt

Objectives: To evaluate the status hepatitis C virus (HCV) treatment among patients in methadone maintenance treatment (MMT) in Long Bien District Medical, Ha Noi City in 2024.
Methods: A cross-sectional descriptive study with analysis on 216 patients in MMT who had hepatitis C.
Results: The rates of untreated and discontinued hepatitis C treatment were high, at 69.4% and 2.8% of patients, respectively. Interviews with patients revealed that 33.3% reported inadequate equipment, medication, and treatment services at treatment facilities. The rate of health insurance coverage was low, with only 6.1% of patients being covered.
Conclusions: The rate of hepatitis C treatment in patients undergoing methadone maintenance therapy is still low, facing many difficulties, especially in terms of cost and treatment time.

Chi tiết bài viết

Tài liệu tham khảo

1. Hepatitis C. , accessed: 11/09/2023.
2. Các tỉnh thúc đẩy điều trị viêm gan C cho người bệnh đồng nhiễm HIV/VGC. ,
accessed: 11/17/2023.
3. WHO calls for increased investment in hepatitis elimination. , accessed: 11/17/2023.
4. Kim T.V., Le D.H., Dao D.V.B., et al. (2022). Demonstration of a population-based HCV serosurvey in Ho Chi Minh City, Viet Nam: Establishing baseline prevalence of and continuum of care for HCV microelimination by 2030. The Lancet Regional Health - Western Pacific, 27.
5. Do S.H., Yamada H., Fujimoto M., et al. (2015). High prevalences of hepatitis B and C virus infections among adults living in Binh Thuan province, Vietnam. Hepatol Res, 45(3), 259-268.
6. CDC Viêm gan vi rút. , accessed: 11/17/2023.
7. Ye S., Pang L., Wang X., et al. (2014). Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia. Curr HIV/ AIDS Rep, 11(2), 128-133.
8. Flower B., Du Hong D., Vu Thi Kim H., et al. (2022). Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis. Lancet Reg Health West Pac, 24, 100468.
9. UNODC (2022), World Drug Report 2022, .
10. Lin M., Kramer J., White D., et al. (2017). Barriers to hepatitis C treatment in the era of directacting anti-viral agents. Alimentary Pharmacology & Therapeutics, 46(10), 992-1000.
11. Vũ Quốc Đạt, Tại Thị Diệu Ngân, Nguyễn Thị Thuý Vân và cộng sự (2023). Tiếp cận chẩn đoán và điều trị viêm gan C tại tuyến huyện: quan điểm từ người bệnh đồng nhiễm viêm gan C/HIV. Tạp chí Nghiên cứu Y học, 164(3).
12. Bộ Y tế (2021). Quyết định 4531/QĐ-BYT Kế hoạch phòng chống bệnh viêm gan vi rút giai đoạn 2021- 2025. .
13. Bộ Y tế (2021). Quyết định 1207/QĐ-BYT 2021 triển khai điều trị viêm gan vi rút C trên người bệnh đồng nhiễm HIV. accessed: 07/15/2024.
14. Murtagh R., Swan D., O’Connor E., et al. (2018). Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study. Interactive Journal of Medical Research, 7(2), e10313.
15. Cullen W., Bury G., Barry J., et al. (2003). Hepatitis C infection among drug users attending general practice. Ir J Med Sci, 172(3), 123-127.
16. Datta S., Horwood J., Hickman M., et al. (2014). Case-finding for hepatitis C in primary care: a mixed-methods service evaluation. Br J Gen Pract, 64(619), e67-e74.
17. Chikovani I., Ompad D.C., Uchaneishvili M., et al. (2019). On the way to Hepatitis C elimination in the Republic of Georgia—Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. PLOS ONE, 14(4), e0216123.
18. Zeremski M., Zibbell J.E., Martinez A.D., et al. (2013). Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World Journal of Gastroenterology, 19(44), 7846-7851.